Dennis Lal, PhD
Lerner Research Institute,
9500 Euclid Avenue, Cleveland, Ohio 44195
Dr. Lal uses genetic data from in-house and globally collected patient cohorts to discover genes related to epilepsy syndromes, to develop novel methods for interpreting missense variants and to characterize patient disease trajectories. Through his research, Dr. Lal hopes to increase our understanding of how alterations in the genome contribute to neurodevelopmental disorders and, ultimately, to improve patient outcomes.
Here are the latest publications:
Dr. Lal and colleagues have developed a statistical model that integrates genetic and clinical data to calculate the probability of developing Dravet syndrome.
Dr. Lal’s team will perform the most comprehensive genetic analysis of focal cortical dysplasia (FCD) to confirm proposed FCD-associated genes and identify novel FCD causal genes and variants.
Dr. Lal’s team conducted the first big data characterization of missense variants from 1,300 disease-associated genes to identify features associated with pathogenic and benign variants.
Dr. Lal adjusted and used a statistical model based on mutation rate to predict the annual number of new cases of over 100 rare monogenetic neurodevelopmental disorders caused by de novo variants, offering previously unavailable estimates for disease burden.
These awards provide Drs. Eng, Lal and Lesmana with seed funding for their highly innovative and potentially impactful cancer research projects.